These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 27809361)
41. A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. Martín-Gago P; Fansa EK; Klein CH; Murarka S; Janning P; Schürmann M; Metz M; Ismail S; Schultz-Fademrecht C; Baumann M; Bastiaens PI; Wittinghofer A; Waldmann H Angew Chem Int Ed Engl; 2017 Feb; 56(9):2423-2428. PubMed ID: 28106325 [TBL] [Abstract][Full Text] [Related]
42. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Ostrem JM; Peters U; Sos ML; Wells JA; Shokat KM Nature; 2013 Nov; 503(7477):548-51. PubMed ID: 24256730 [TBL] [Abstract][Full Text] [Related]
44. Discovery of novel KRAS‒PDE Chen L; Zhang J; Wang X; Li Y; Zhou L; Lu X; Dong G; Sheng C Acta Pharm Sin B; 2022 Jan; 12(1):274-290. PubMed ID: 35127385 [TBL] [Abstract][Full Text] [Related]
45. Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis. Messina S Small GTPases; 2020 Sep; 11(5):312-319. PubMed ID: 30043672 [TBL] [Abstract][Full Text] [Related]
46. Galectin-8 binds to the Farnesylated C-terminus of K-Ras4B and Modifies Ras/ERK Signaling and Migration in Pancreatic and Lung Carcinoma Cells. Meinohl C; Barnard SJ; Fritz-Wolf K; Unger M; Porr A; Heipel M; Wirth S; Madlung J; Nordheim A; Menke A; Becker K; Giehl K Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861875 [TBL] [Abstract][Full Text] [Related]
47. RNA aptamers that specifically bind to a K Ras-derived farnesylated peptide. Gilbert BA; Sha M; Wathen ST; Rando RR Bioorg Med Chem; 1997 Jun; 5(6):1115-22. PubMed ID: 9222505 [TBL] [Abstract][Full Text] [Related]
48. A novel prenyl-polybasic domain code determines lipid-binding specificity of the K-Ras membrane anchor. Zhou Y; Hancock JF Small GTPases; 2020 May; 11(3):220-224. PubMed ID: 29239694 [TBL] [Abstract][Full Text] [Related]
50. Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells. Guo M; He S; Cheng J; Li Y; Dong G; Sheng C ACS Med Chem Lett; 2022 Feb; 13(2):298-303. PubMed ID: 35178186 [TBL] [Abstract][Full Text] [Related]
51. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo. Cruz-Nova P; Schnoor M; Correa-Basurto J; Bello M; Briseño-Diaz P; Rojo-Domínguez A; Ortiz-Mendoza CM; Guerrero-Aguirre J; García-Vázquez FJ; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M BMC Cancer; 2018 Nov; 18(1):1056. PubMed ID: 30382908 [TBL] [Abstract][Full Text] [Related]
52. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Van Sciver RE; Lee MP; Lee CD; Lafever AC; Svyatova E; Kanda K; Colliver AL; Siewertsz van Reesema LL; Tang-Tan AM; Zheleva V; Bwayi MN; Bian M; Schmidt RL; Matrisian LM; Petersen GM; Tang AH Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29757973 [TBL] [Abstract][Full Text] [Related]
53. Inhibitors of chronically active ras: potential for treatment of human malignancies. Blum R; Cox AD; Kloog Y Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):31-47. PubMed ID: 18289122 [TBL] [Abstract][Full Text] [Related]
54. Properties of the interaction of Arf-like protein 2 with PDEdelta. Hanzal-Bayer M; Linari M; Wittinghofer A J Mol Biol; 2005 Jul; 350(5):1074-82. PubMed ID: 15979089 [TBL] [Abstract][Full Text] [Related]
55. Discovery of Turn-On Fluorescent Probes for Detecting PDEδ Protein in Living Cells and Tumor Slices. Dong G; Chen L; Zhang J; Liu T; Du L; Sheng C; Li M Anal Chem; 2020 Jul; 92(14):9516-9522. PubMed ID: 32571022 [TBL] [Abstract][Full Text] [Related]
56. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980 [TBL] [Abstract][Full Text] [Related]
57. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432 [TBL] [Abstract][Full Text] [Related]
58. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Rotblat B; Ehrlich M; Haklai R; Kloog Y Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183 [TBL] [Abstract][Full Text] [Related]
59. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Sun J; Qian Y; Hamilton AD; Sebti SM Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745 [TBL] [Abstract][Full Text] [Related]
60. Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis. Prakash P; Zhou Y; Liang H; Hancock JF; Gorfe AA Biophys J; 2016 Mar; 110(5):1125-38. PubMed ID: 26958889 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]